share_log

長江生命科技：二零二四年度全年業績

CKLIFE SCIENCES: ANNUAL RESULTS FOR 2024

HKEX ·  Mar 18 10:16

Summary by Moomoo AI

長江生命科技於2024年度錄得股東應佔虧損港幣1.27億元，相比2023年度溢利港幣1,730萬元，轉盈為虧。業績倒退主要受兩大因素影響：科研投資支出大幅增加至港幣2.54億元，較去年增加港幣1.08億元；以及葡萄園投資組合公平值錄得稅後貶值港幣4,040萬元。集團保健產品業務表現穩健，溢利按年增長3%至港幣2.93億元。Vitaquest成功獲取美國藥典認證，Lipa榮獲澳洲保健藥品協會頒發可持續大獎，而SNAG則透過新配方及市場策略把握後疫情商機。農業相關業務方面，撇除公平值變動，基礎溢利貢獻為港幣3.24億元，較去年上升4%。展望未來，公司將繼續投資於後期研發項目，預期短期內將影響股東應佔溢利。在醫藥研發方面，公司重點發展痛楚舒緩及癌症療法，其中Halneuron®計劃於2025年第一季展開第二期B階段臨床試驗。此外，公司亦策略性投資於液體活檢測試項目，以開發非入侵性及具成本效益之癌症檢測方案。
長江生命科技於2024年度錄得股東應佔虧損港幣1.27億元，相比2023年度溢利港幣1,730萬元，轉盈為虧。業績倒退主要受兩大因素影響：科研投資支出大幅增加至港幣2.54億元，較去年增加港幣1.08億元；以及葡萄園投資組合公平值錄得稅後貶值港幣4,040萬元。集團保健產品業務表現穩健，溢利按年增長3%至港幣2.93億元。Vitaquest成功獲取美國藥典認證，Lipa榮獲澳洲保健藥品協會頒發可持續大獎，而SNAG則透過新配方及市場策略把握後疫情商機。農業相關業務方面，撇除公平值變動，基礎溢利貢獻為港幣3.24億元，較去年上升4%。展望未來，公司將繼續投資於後期研發項目，預期短期內將影響股東應佔溢利。在醫藥研發方面，公司重點發展痛楚舒緩及癌症療法，其中Halneuron®計劃於2025年第一季展開第二期B階段臨床試驗。此外，公司亦策略性投資於液體活檢測試項目，以開發非入侵性及具成本效益之癌症檢測方案。
In the fiscal year 2024, CKLIFE SCIENCES recorded a Shareholder's attributable loss of HKD 0.127 billion, compared to a profit of HKD 17.3 million in 2023, marking a shift from profit to loss. The decline in performance was mainly affected by two major factors: a significant increase in research and development expenditure to HKD 0.254 billion, which is HKD 0.108 billion more than last year; and a post-tax depreciation of HKD 40.4 million recorded in the vineyard investment portfolio's fair value.The group's health products Business performed steadily, with profits growing 3% year-on-year to HKD 0.293 billion. Vitaquest successfully obtained certification from the United States Pharmacopeia, Lipa received the Sustainable Excellence Award from the Australian Health Products Association, and SNAG capitalized on post...Show More
In the fiscal year 2024, CKLIFE SCIENCES recorded a Shareholder's attributable loss of HKD 0.127 billion, compared to a profit of HKD 17.3 million in 2023, marking a shift from profit to loss. The decline in performance was mainly affected by two major factors: a significant increase in research and development expenditure to HKD 0.254 billion, which is HKD 0.108 billion more than last year; and a post-tax depreciation of HKD 40.4 million recorded in the vineyard investment portfolio's fair value.The group's health products Business performed steadily, with profits growing 3% year-on-year to HKD 0.293 billion. Vitaquest successfully obtained certification from the United States Pharmacopeia, Lipa received the Sustainable Excellence Award from the Australian Health Products Association, and SNAG capitalized on post-pandemic opportunities through new formulations and market strategies. In terms of Agriculture-related Business, excluding fair value changes, the basic profit contribution was HKD 0.324 billion, an increase of 4% from last year.Looking ahead, the company will continue to invest in late-stage research and development projects, which are expected to impact Shareholder's attributable profit in the short term. In pharmaceutical research and development, the company focuses on pain relief and cancer treatment, with the Halneuron® project planned to enter the Phase II B clinical trial in Q1 2025. Additionally, the company is strategically investing in liquid biopsy testing projects to develop non-invasive and cost-effective cancer detection solutions.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 262

Recommended

Related Stocks Related Stocks
Symbol Mini Chart Price
SANAI HEALTH GP
01889
0.290
TIANDA PHARMA
00455
0.184
AIM VACCINE
06660
4.550
HANSOH PHARMA
03692
21.050
PAK FAH YEOW
00239
2.170
Log In for the Full List
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More
FOMC Press Conference, March 19, 2025

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
OK